Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences

31 Aug 2018

Merck adds to its stagnating HIV portfolio with US approvals of doravirine and a three-drug combo including the NNRTI, but the combo’s potential may be limited due to inclusion of an older version of tenofovir.

Form close up, fountain pen and approved stamped on a document. Soft focus.

An ahead-of-schedule approval is always good news, but it’s unclear how much Merck & Co. Inc. will benefit from the US FDA nods for two news HIV therapies, novel non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine) on its own and as part of the three-drug combination pill Delstrigo.

The two products obtained US FDA approval for treatment-naïve HIV-1-infected patients on Aug. 30, nearly two months ahead of their...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

23 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

20 Jun 2025

• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

19 Jun 2025

• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.